Division of Cardiology, University of Washington Medical Center, Seattle, WA.
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
Am Heart J. 2014 Nov;168(5):721-30. doi: 10.1016/j.ahj.2014.07.008. Epub 2014 Jul 22.
Studies on outcomes among patients with heart failure (HF) with preserved left ventricular ejection fraction (HFpEF), borderline left ventricular ejection fraction (HFbEF), and reduced left ventricular ejection fraction (HFrEF) remain limited. We sought to characterize mortality and readmission in patients with HF in the contemporary era.
Get With The Guidelines-HF was linked to Medicare data for longitudinal follow-up. Patients were grouped into HFpEF (left ventricular ejection fraction [EF] ≥ 50%), HFbEF (40% ≤ EF < 50%), and HFrEF (EF < 40%). Multivariable models were constructed to examine the relationship between EF and outcomes at 30 days and 1 year and to study trends over time.
A total of 40,239 patients from 220 hospitals between 2005 and 2011 were included in the study: 18,897 (47%) had HFpEF, 5,626 (14%) had HFbEF, and 15,716 (39%) had HFrEF. In crude survival analysis, patients with HFrEF had slightly increased mortality compared with HFbEF and HFpEF. After risk adjustment, mortality at 1 year was not significantly different for HFrEF, HFbEF, and HFpEF (HFrEF vs HFpEF, hazard ratio [HR] 1.040 [95% CI 0.998-1.084], and HFbEF vs HFpEF, HR 0.967 [95% CI 0.917-1.020]). Patients with HFpEF had increased risk of all-cause readmission compared with HFrEF. Conversely, risk of cardiovascular and HF readmissions were higher in HFrEF and HFbEF compared with HFpEF.
Among patients hospitalized with HF, patients with HFpEF and HFbEF had slightly lower mortality and higher all-cause readmission risk than patients with HFrEF, although the mortality differences did not persist after risk adjustment. Irrespective of EF, these patients experience substantial mortality and readmission highlighting the need for new therapeutic strategies.
目前对于左心室射血分数保留型心力衰竭(HFpEF)、左心室射血分数中间值型心力衰竭(HFbEF)和射血分数降低型心力衰竭(HFrEF)患者结局的研究仍然有限。本研究旨在描述当代心力衰竭患者的死亡率和再入院率。
将“Get With The Guidelines-Heart Failure”注册研究与 Medicare 数据相链接进行纵向随访。将患者分为 HFpEF(左心室射血分数 [EF]≥50%)、HFbEF(40%≤EF<50%)和 HFrEF(EF<40%)。构建多变量模型以检验 EF 与 30 天和 1 年时结局的关系,并研究随时间的变化趋势。
共纳入 2005 年至 2011 年来自 220 家医院的 40239 例患者:18897 例(47%)为 HFpEF,5626 例(14%)为 HFbEF,15716 例(39%)为 HFrEF。在粗死亡率分析中,与 HFbEF 和 HFpEF 相比,HFrEF 患者的死亡率略有升高。经风险调整后,HFrEF、HFbEF 和 HFpEF 患者的 1 年死亡率无显著差异(HFrEF 与 HFpEF 相比,风险比 [HR]1.040 [95%置信区间 0.998-1.084],HFbEF 与 HFpEF 相比,HR 0.967 [95%置信区间 0.917-1.020])。与 HFrEF 相比,HFpEF 患者的全因再入院风险增加。相反,与 HFpEF 相比,HFrEF 和 HFbEF 患者的心血管和 HF 再入院风险更高。
在因心力衰竭住院的患者中,HFpEF 和 HFbEF 患者的死亡率略低于 HFrEF 患者,全因再入院风险较高,但经风险调整后死亡率差异并不显著。无论 EF 如何,这些患者的死亡率和再入院率均较高,突显了新的治疗策略的必要性。